These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49 related articles for article (PubMed ID: 1473878)
1. Evaluation of monoclonal/polyclonal ratio in kidney-transplanted patients treated with cyclosporine. Capone D; Stanziale P; Balletta MM; Imperatore P; De Marino V; Pisanti N Int J Clin Pharmacol Res; 1992; 12(3):123-8. PubMed ID: 1473878 [TBL] [Abstract][Full Text] [Related]
2. Polyclonal/monoclonal ratio in kidney and bone marrow transplanted patients treated with cyclosporine. Capone D; De Marino V; Caso N; Stanziale P; Fontana R; Imperatore P; De Marino V; Pisanti N Clin Transplant; 1998 Oct; 12(5):430-3. PubMed ID: 9787953 [TBL] [Abstract][Full Text] [Related]
3. Induction therapy with cyclosporine without cytolytic agents results in a low incidence of acute rejection without significant renal impairment in heart transplant patients. Jazzar A; Fagiuoli S; Sisson S; Zuhdi N; Cooper DK Clin Transplant; 1995 Aug; 9(4):334-9. PubMed ID: 7579743 [TBL] [Abstract][Full Text] [Related]
4. Is there a relation between cycloporine trough levels and endomyocardial biopsy score after heart transplantation? Cantarovich M; Latter D; Fitchett D Transplant Proc; 1994 Oct; 26(5):2725-6. PubMed ID: 7940854 [No Abstract] [Full Text] [Related]
5. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Moroni G; Doria A; Mosca M; Alberighi OD; Ferraccioli G; Todesco S; Manno C; Altieri P; Ferrara R; Greco S; Ponticelli C Clin J Am Soc Nephrol; 2006 Sep; 1(5):925-32. PubMed ID: 17699309 [TBL] [Abstract][Full Text] [Related]
6. Importance of cyclosporine dosage and blood levels in simultaneous pancreas and kidney transplant success. Cantarovich D; Dantal J; Hourmant M; Baatard R; Paineau J; Murat A; Soulillou JP Transplant Proc; 1992 Jun; 24(3):890-1. PubMed ID: 1604657 [No Abstract] [Full Text] [Related]
7. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Sandborn WJ; Hay JE; Porayko MK; Gores GJ; Steers JL; Krom RA; Wiesner RH Hepatology; 1994 Apr; 19(4):925-32. PubMed ID: 8138267 [TBL] [Abstract][Full Text] [Related]
8. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3). Noël C; Hazzan M; Coppin MC; Pruvot FR; Bridoux F; Lelièvre G Transplant Proc; 1995 Aug; 27(4):2438-9. PubMed ID: 7652870 [No Abstract] [Full Text] [Related]
9. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. Herman M; Weinstein T; Korzets A; Chagnac A; Ori Y; Zevin D; Malachi T; Gafter U J Lab Clin Med; 2001 Jan; 137(1):14-20. PubMed ID: 11150019 [TBL] [Abstract][Full Text] [Related]
10. Cyclosporine monotherapy versus conventional therapy in the living-related renal transplant: a one center retrospective study. Masri MA; Shakuntala V; Dhawan IK; Zahir M; Shanwaz M; Hayes K; Pingle A Transplant Proc; 1993 Jun; 25(3):2248-9. PubMed ID: 8516889 [No Abstract] [Full Text] [Related]
11. Immunosuppressive protocols at transplantation centers in Turkey. Haberal M; Demirağ A; Bilgin N; Arslan G; Büyükpamukçu N Transplant Proc; 1995 Oct; 27(5):2776-7. PubMed ID: 7482911 [No Abstract] [Full Text] [Related]
12. A controlled prospective trial of triple therapy with low-dose azathioprine, cyclosporine, and methylprednisolone in renal transplantation. De Vecchi A; Tarantino A; Montagnino G; Egidi F; Vegeto A; Berardinelli L; Ponticelli C Transplant Proc; 1987 Feb; 19(1 Pt 3):1933-4. PubMed ID: 3079060 [No Abstract] [Full Text] [Related]
13. Effects of cyclosporine A on chronic renal transplant rejection. Pabico RC; Yarger J; Byer B; Kremer M; McKenna BA; Cerilli GJ Transplant Proc; 1994 Oct; 26(5):2577-9. PubMed ID: 7940798 [No Abstract] [Full Text] [Related]
15. Kidney transplantation at extremes of age: CsA eliminates the increased risk in recipients < or = 5 or > or = 55 years. MacDonell RC; Van Buren DH; Richie RE; Johnson HK; Nylander WA; Helderman JH; Ynares CM; Trusler LA; Green WF; Crowe DA Transplant Proc; 1994 Oct; 26(5):2518-21. PubMed ID: 7940774 [No Abstract] [Full Text] [Related]
16. Strategy for improvement of graft survival in kidney recipients of nonrelated living donors. Távora ER; Lasmar EP; Vilaca SS; Figueiró JV; Bamberg A; Rocha LM; Costa MM; Bicalbo O; Souza E; Machado R Transplant Proc; 1995 Apr; 27(2):1819-20. PubMed ID: 7725518 [No Abstract] [Full Text] [Related]
17. Kidney function in cyclosporine-treated pediatric heart transplant recipients. Laine J; Jalanko H; Leijala M; Sairanen H; Holmberg C J Heart Lung Transplant; 1997 Dec; 16(12):1217-24. PubMed ID: 9436133 [TBL] [Abstract][Full Text] [Related]
18. Malignant neoplasms in renal transplant patients: a 24-year experience. Bordes-Aznar J; Mancilla E; Rosenblum M; Gabilondo F; Orozco R; Angeles A; Alberú J Transplant Proc; 1992 Oct; 24(5):1802-3. PubMed ID: 1412851 [No Abstract] [Full Text] [Related]
19. Treatment of acute renal transplant rejection with FK 506 in patients on cyclosporine after failure of standard antirejection therapy. Scott-Douglas N; Zimmerman D; Klassen J Transplant Proc; 1996 Dec; 28(6):3165. PubMed ID: 8962226 [No Abstract] [Full Text] [Related]
20. Reduction of immunosuppressive therapy after renal transplantation: a randomized study. Heering P; Westhoff A; Ivens K; Kutkuhn B; Grabensee B Transplant Proc; 1994 Oct; 26(5):2530-2. PubMed ID: 7940778 [No Abstract] [Full Text] [Related] [Next] [New Search]